Federal Cannabis Rescheduling: Where We Are Now

DEA, FDA, and the Road from Schedule I to Schedule III

Topic Summary

The DEA's proposed reclassification of cannabis to Schedule III marks the most consequential federal shift in 50 years of U.S. drug policy. Robert Hoban unpacks the rulemaking timeline, what rescheduling does — and critically does not — change for operators, the IRC §280E tax survival path, and what the industry should expect next from DEA, FDA, and Congress. This session separates signal from noise for counsel, operators, and investors navigating the transition.

Session Outline

I. The Rulemaking Timeline

›DEA Notice of Proposed Rulemaking: key dates and comment period
›HHS recommendation mechanics and evidentiary basis
›Projected final-rule effective date and interim period

II. What Schedule III Actually Changes

›IRC §280E: the most misunderstood piece of the rescheduling story
›Federal criminal exposure: possession, distribution, and trafficking thresholds
›Banking and financial services: what SAFE Banking does (and doesn't) do in parallel
›State-level crossover: markets that stay illegal under state law vs. federal-only liberalization

III. What Rescheduling Does NOT Change

›Federal agency jurisdiction (FDA, USDA, FTC) stays intact
›Interstate commerce remains prohibited without additional legislation
›Export and import: no change for international operators
›Cannabis-specific banking regulations

IV. Implications by Stakeholder

›MSOs: tax savings timeline, capital strategy, M&A valuations
›Single-state operators: IRS audit posture in the transition gap
›In-house counsel: updating compliance manuals and board disclosures
›Investors: how public company disclosures change

V. What Comes After Schedule III

›Congressional pathways: SAFER Banking, STATES Act, descheduling proposals
›FDA regulatory framework for cannabis as a drug vs. agricultural commodity
›International treaty obligations (1961 Single Convention)

VI. Q&A

Suggested Formats

Keynote (45 min)Panel (60 min)Fireside Chat (30 min)

Best for These Audiences

In-House CounselCannabis OperatorsInvestorsPolicy Makers

Book this topic

Request “Federal Cannabis Rescheduling: Where We Are Now”

Submit a booking inquiry and our team will follow up within 2–3 business days with availability, fee details, and logistics.

Submit a Booking Inquiry